GlassScriptPhysician profile
Jason K Taylor
NPI 1649481607
$173,016.16
in general payments reported to CMS, 2019-2025
30 companies · $7,557 in 2025
The $7,557 reported for 2025 was more than what 89% of Rheumatology providers received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $58K · 2020: $10K · 2021: $33K · 2022: $38K · 2023: $13K · 2024: $13K · 2025: $7,557.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $26K · Food and Beverage: $8,053 · Education: $91.95.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $25,860.00 |
| Food and Beverage | $8,052.95 |
| Education | $91.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $82,265.28 | 2019-2025 | Rinvoq, Skyrizi |
| Novartis Pharmaceuticals Corporation | $22,540.58 | 2019-2025 | |
| Amgen INC. | $16,136.78 | 2019-2025 | Enbrel, Otezla, Tavneos |
| Mallinckrodt Enterprises LLC | $13,166.23 | 2019 | |
| Mallinckrodt Hospital Products INC. | $11,015.27 | 2020-2025 | Acthar |
| Pfizer INC. | $9,661.07 | 2019-2025 | |
| Glaxosmithkline, LLC. | $7,714.90 | 2019-2025 | Benlysta |
| Janssen Biotech, INC. | $6,771.42 | 2019-2025 | Tremfya, Simponi Aria, Stelara |
| Ani Pharmaceuticals, INC. | $651.35 | 2022-2025 | Purified Cortrophin Gel |
| Ucb, INC. | $639.93 | 2019-2025 | Cimzia, Bimzelx |
| E.R. Squibb & Sons, L.L.C. | $542.49 | 2019-2025 | Orencia, Sotyktu |
| Lilly USA, LLC | $444.13 | 2019-2023 | Taltz |
| Horizon Therapeutics Plc | $281.79 | 2019-2023 | Krystexxa |
| Aurinia Pharma U.S., INC. | $212.83 | 2021-2025 | Lupkynis |
| Astrazeneca Pharmaceuticals LP | $163.64 | 2021-2024 | Saphnelo |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $159.57 | 2021-2025 | Cyltezo, Ofev |
| Genentech USA, INC. | $124.72 | 2019-2020 | |
| Radius Health, INC. | $94.52 | 2019-2024 | |
| Genzyme Corporation | $89.78 | 2020-2025 | |
| Invivyd INC | $63.84 | 2025 | Pemgarda |
| Alexion Pharmaceuticals, INC. | $44.01 | 2025 | Strensiq |
| Organon LLC | $42.82 | 2024-2025 | Hadlima |
| Fresenius Kabi USA, LLC | $39.91 | 2023 | Idacio |
| Hikma Pharmaceuticals USA | $26.55 | 2022 | |
| Medexus Pharma, INC. | $25.94 | 2019 | |
| Abbott Laboratories | $25.24 | 2024 | Eterna |
| Takeda Pharmaceuticals U.S.A., INC. | $21.80 | 2019 | |
| Assertio Therapeutics, INC. | $17.61 | 2019 | |
| Sobi, INC | $17.03 | 2020 | |
| Mylan Institutional INC. | $15.13 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jason Taylor listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.